CEL-SCI Corporation Stock News

In our last article, we provided ten reasons why we believe FDA approval of CEL-SCI's drug Multikine and concomitant multibillion dollar valuation is highly likely. This article addresses the critics'

CEL-SCI announced successful Phase III clinical trial results of its drug Multikine, which can treat 155,000 newly diagnosed advanced primary head and neck cancer patients per year globally. Five-year

The stock price of CEL-SCI Corporation (NYSEAMERICAN: CVM) increased 8.5%. This is why it happened.

The company attempted to clarify "confusion" related to its recent late-stage clinical results.

New York, New York--(Newsfile Corp. - July 5, 2021) - Pomerantz LLP is investigating claims on behalf of investors of CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM). Such invest

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #HeadandNeckCancer--The discussion of the results of CEL-SCI's Phase 3 Trial is now available.

CEL-SCI Corporation (NASDAQ:CVM) shares are trading lower by 27% at $9.33 on continued downward momentum following data from a Phase 3 Study of Multkine showing a 14.1% 5-year survival benefit in gr

Everything went the wrong way for Cel-Sci.

NEW YORK, June 29, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE: CVM).  Such investors are advise

Today, the trial results reported by Cel-Sci missed the mark, and investors are pricing in additional risks with CVM stock. The post CVM Stock: The Big Trial News That Has Cel-Sci Plunging Today appea

VIENNA, Va.--(BUSINESS WIRE)---- $CVM #Multikine--Multikine immunotherapy produces significant 14.1% 5-Year survival benefit in group receiving surgery plus radiotherapy in landmark Phase 3 Study.

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Corporation invites participants to pre-submit questions for Annual Shareholder Meeting.

CEL-SCI Corporation (NYSE: CVM) has increased the size of its previously announced capital raise offering to 1.4 million shares, up from 1 million shares, at $22.62 per share representing a 5% dis

VIENNA, Va.--(BUSINESS WIRE)---- $CVM--CEL-SCI Increases Previously Announced Bought Deal to $31.7 Million.

VIENNA, Va.--(BUSINESS WIRE)-- #CVM--CEL-SCI Announces Bought Deal Offering